- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03535571
A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females
A Proof-of-concept Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5R8
- KGK Science Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female, 30-60 years of age
Female participant is not of child bearing potential, defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) or,
Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method
- Intrauterine devices
- Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner (shown successful as per appropriate follow-up)
- BMI of 18.5 kg/m²-32.5 kg/m²
- Agrees to comply with study procedures
- Willing to commit to taking product for 128 days
- Agrees to provide voluntary, written, informed consent to participate in the study
- Agrees to maintain normal diet and exercise routine throughout the study
- Healthy as determined by medical history, medical physical test for good health, and laboratory results
Exclusion Criteria:
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
- Blood donation during or within 30 days of the last study visit
- Taking any specific energy supplements or vitamins at least 1 month prior to and during the trial as assessed by the QI
- Unstable weight for the last 2 months prior to the study assessed case by case by QI
- Individuals on a low protein diet
- Excessive consumption of alcohol equivalent to >2 alcoholic drinks/day
- Use of marijuana assessed case by case by QI
- Known allergy to the test material's active or inactive ingredients
- Clinically significant abnormal Physical Examination results at screening
- Participation in clinical trials in the past 30 days
- Cognitively impaired and/or unable to give informed consent
- current cardiovascular disorders or uncontrolled blood pressure will be assessed by QI)
- Verbal confirmation of history of or current diagnosis of bleeding/blood disorder
- Verbal confirmation of Type I or Type II diabetes
- Verbal confirmation of kidney disease
- Verbal confirmation of history of liver disease
- Anemia based on hemoglobin and hematocrit at screening
- Thyroid disease assessed case by case by QI
- Iron Supplementation
- Mood stabilizers assessed case by case by QI
- Energy boosting supplements
- Individuals on workout supplements
- Habitual users of energy drinks
- Melatonin supplementation assessed case by case by QI
- Autoimmune disease or if immune-compromised (i.e. HIV positive, use of anti-rejection medication, rheumatoid arthritis, Hepatitis B/C positive)
- Surgical procedures which may impact the study outcomes within the past 3 months to be assessed by the QI
- Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission will be assessed by the QI for inclusion.
- Presence or history of neurological disorders or significant psychiatric illness as assessed by QI
- Any other condition, in the QI's opinion, which may adversely affect the participant's ability to complete the study or its measures or which may pose significant risk to the participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Salmon Protein Hydrolysate (CollaGo®)
Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.
|
4g of salmon protein hydrolysate per serving.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Change From Baseline (Day 0) to End-of-study (Day 128) in Energy Level After a 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
This questionnaire consists of a total of 30 questions that assess vitality and quality of life. The responses for these questions range from 1 to 7, where 1 indicates "never" or "not at all true" 4 indicates "sometimes" or "somewhat true" and 7 indicates "always" or "very true" depending on the item that is assessed by the question. 15 of the 30 questions are positively keyed in which a higher score indicates a better outcome and remaining 15 questions are negatively keyed where a lower score indicates a better outcome. The responses on the negatively keyed questions will be reversed prior to calculating the total score (i.e. a response of 1 will be considered as 7, 2 will be considered as 6, etc.). Total range will be 30-210, where a higher total score indicates a better outcome and a lower total score indicates a worse outcome. |
Baseline (Day 0) to end-of-study (Day 128)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Day 128 in Red Blood Cell (RBC) Count After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
|
Change From Baseline to Day 128 in Mean Corpuscular Volume (MCV) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
|
Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin (MCH) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
|
Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin Concentration (MCHC) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
|
Change From Baseline to Day 128 in Hematocrit After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
|
Change From Baseline to Day 128 in Red Cell Distribution Width (RDW) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
|
Change From Baseline to Day 128 in Hemoglobin (Hb) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
|
Change From Baseline to Day 128 in Relative Expression of 84 Stress Genes After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Evaluated by oxidative stress-related gene RT Profiler PCR array.
Seven of the 84 genes were upregulated, which are highlighted in the results.
|
Baseline (Day 0) to end-of-study (Day 128)
|
Change From Baseline to Day 128 in Total Reactive Oxygen Species/Reactive Nitrogen Species Free Radical Activity After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Assessed by ROS/RNS assay
|
Baseline (Day 0) to end-of-study (Day 128)
|
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-1 Alpha After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Measured by the Multi-Analyte ELISArray
|
Baseline (Day 0) to end-of-study (Day 128)
|
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-4 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Measured by the Multi-Analyte ELISArray
|
Baseline (Day 0) to end-of-study (Day 128)
|
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-6 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Measured by the Multi-Analyte ELISArray
|
Baseline (Day 0) to end-of-study (Day 128)
|
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-10 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Measured by the Multi-Analyte ELISArray
|
Baseline (Day 0) to end-of-study (Day 128)
|
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-11 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Measured by the Multi-Analyte ELISArray.
|
Baseline (Day 0) to end-of-study (Day 128)
|
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-13 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Measured by the Multi-Analyte ELISArray
|
Baseline (Day 0) to end-of-study (Day 128)
|
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine TGF-Beta After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Measured by the Multi-Analyte ELISArray
|
Baseline (Day 0) to end-of-study (Day 128)
|
Change From Baseline to Day 128 in Glycated Hemoglobin (HbA1c) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
|
Change From Baseline to Day 128 in Fasting Glucose After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
|
Change in Score of the Hair, Nails, and Skin Self-Assessment Questionnaire After 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
This questionnaire consists of a total of 7 questions that assess the participant's perception on hair (4 questions), nail (1 question) and skin health (2 question). The response to each question can range from 1 to 6 where 1 indicates "greatly satisfied" and 6 indicates "greatly dissatisfied". The range for the total score on this questionnaire is 7-42. Lower total score indicates a better outcome, and higher total score indicates a worse outcome. |
Baseline (Day 0) to end-of-study (Day 128)
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Incidence of Adverse Events Following a 128-day Supplementation
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
The Effect of a 128-day Supplementation on Weight
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
The Effect of a 128-day Supplementation on Blood Pressure
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
The Effect of a 128-day Supplementation on Heart Rate
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
The Effect of a 128-day Supplementation on Waist Circumference
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
The Effect of a 128-day Supplementation on Hip Circumference
Time Frame: Baseline (Day 0) to end-of-study (Day 128)
|
Baseline (Day 0) to end-of-study (Day 128)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 18PEHH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Salmon Protein Hydrolysate
-
University of BergenBlueProtein; NutriMarCompletedObesity | OverweightNorway
-
Helse Møre og Romsdal HFHaukeland University HospitalCompletedHealthy VolunteersNorway
-
Natural Immune Systems IncRecruiting
-
BioActorCompletedMuscle Strength Recovery
-
Atlantia Food Clinical TrialsTerminated
-
Stanford UniversityNot yet recruitingUlcerative ColitisUnited States
-
Molde University CollegeCompleted
-
Chung Shan Medical UniversityNational Taichung University of EducationCompleted
-
University of UlsterUniversity of Limerick; Bio-Marine Ingredients IrelandNot yet recruiting
-
Maastricht University Medical CenterCompletedType 2 Diabetes Mellitus | Impaired Glucose Tolerance | Dietary Modification | Arterial StiffnessNetherlands